OPERA-01 Phase 3 study is for people with advanced and/or metastatic ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitors and endocrine therapy.
Pursuing better treatments to help patients feel better, longer.
Bring your passion, join our team and make your mark.
Olema's latest news and recent events.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor